• 검색 결과가 없습니다.

Journal of Breast Cancer

N/A
N/A
Protected

Academic year: 2021

Share "Journal of Breast Cancer"

Copied!
1
0
0

로드 중.... (전체 텍스트 보기)

전체 글

(1)

© 2017 Korean Breast Cancer Society. All rights reserved. http://ejbc.kr | pISSN 1738-6756 eISSN 2092-9900

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/

licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

J Breast Cancer 2017 December; 20(4): 408 http://dx.doi.org/10.4048/jbc.2017.20.4.408

Journal of Breast Cancer

Follow-up Outcomes of Benign Pathology Initially Assigned as Breast Imaging Reporting and Data System Category 4A and 3

Ji Young You, Hee Jung Suh

1

, Yunju Kim, Jae Kwan Jun

2

, Haydee Ojeda-Fournier

3

, Kyounglan Ko

Center for Breast Cancer, Research Institute and Hospital, 1Cancer Prevention and Early Detection Center, and 2National Cancer Control Institute, National Cancer Center, Goyang, Korea; 3Department of Radiology, Moores Cancer Center, UC San Diego Health System, La Jolla, USA

Erratum to: J Breast Cancer 2017 Sep;20(3):304-309. English.

Published online Sep 22, 2017. https://doi.org/10.4048/jbc.2017.20.3.304

This article was initially published on the Journal of Breast Cancer with a misspelled the Institutional Review Board (IRB) approval number.

The IRB number should be corrected as “NCC2014-0031”.

ERRATUM

Correspondence to: Kyounglan Ko

Center for Breast Cancer, Research Institute and Hospital, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea

Tel: +82-31-920-1644, Fax: +82-31-920-1226 E-mail: [email protected]

This work was supported by grant from the National Cancer Center Korea (1310250-1).

Received: May 19, 2017 Accepted: September 1, 2017

참조

관련 문서

Results: 44 of 1048 patients with gastric cancer(4.1%) had synchronous and metachronous cancers. The average time interval between gastric cancer and secondary primary cancer

3yr Distant control rate (%) RT alone vs.. 2) Erbitux based concurrent chemoradiotherapy (CCRTx)는 cisplatin based CCRTx보다 생존율을 증가시킨다. 3) Erbitux

• 2001년에 미국 국립보건원 National Institute of Health, NIH 에서 주최한 암환자 증상관리 학회 State of the Science Conference on Symptom Management in Cancer 에서

Ministry of Economic Affairs, R.O.C. Innovation and Incubation Center, National Kaohsiung University of Science and Technology 、 Institute For Information

Patients with breast cancer; ovarian cancer; renal cell carcinoma; pancreatic neuroendocrine cancer; colorectal cancer; head and neck cancer; non-small cell lung

• Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)..

Specifically, the prevalence and incidence rates of cancer among chronic diseases are continuously increasing, while early diagnosis and treatment of cancer

Analysing this research material, The present study were examined that extravasated blood and cancer had interrelationship by comparing cancer patients